T regulatory cells, the evolution of targeted immunotherapy.
T regulatory cells are able to suppress anti-tumour immunity in pre-clinical models and in patients. This review highlights the important discoveries in Treg immunology critical to the evolution of targeted immunotherapy. We also describe the therapeutic applications that are currently being assessed and their future potential.
Nizar
S
S
Department of Cellular and Molecular Medicine, St George's University of London, UK.
Meyer
B
B
Galustian
C
C
Kumar
D
D
Dalgleish
A
A
D000818:Animals; D015703:Antigens, CD / Q000502:physiology; D060908:CTLA-4 Antigen; D003713:Dendritic Cells / Q000276:immunology; D051858:Forkhead Transcription Factors / Q000502:physiology; D006801:Humans; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000502:physiology*
D015703:Antigens, CD; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors